Halozyme Therapeutics, Inc. vs. Moderna, Inc. Common Stock
Halozyme Therapeutics, Inc. and Moderna, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| HALO | MRNA | |
|---|---|---|
| Market Cap | $11.90 billion | $25.14 billion |
| Revenue (TTM) | $1.66 billion | $2.23 billion |
| Net Income (TTM) | $413.60 million | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| HALO | MRNA | |
|---|---|---|
| P/E Ratio | 31.47 | — |
| Price / Book | 82.94 | 3.72 |
| Price / Sales | 7.16 | 11.28 |
HALO and MRNA split the valuation factors evenly.
Profitability
| HALO | MRNA | |
|---|---|---|
| Net Margin | 24.86% | -141.43% |
| Return on Equity | 288.13% | -46.61% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | MRNA | |
|---|---|---|
| Short Interest | 9.79% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.